Endometriosis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Endometriosis – Pipeline Review, H2 2017’, provides an overview of the Endometriosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Endometriosis

The report reviews pipeline therapeutics for Endometriosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Endometriosis therapeutics and enlists all their major and minor projects

The report assesses Endometriosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Endometriosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Endometriosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Addex Therapeutics Ltd

APAvadis Biotechnologies Srl

Astellas Pharma Inc

Bayer AG

ElexoPharm GmbH

EndoCeutics Inc

Enteris BioPharma Inc

Evotec AG

Forendo Pharma Ltd

Kissei Pharmaceutical Co Ltd

Lipicard Technologies Ltd

Luye Pharma Group Ltd

Nippon Shinyaku Co Ltd

Ogeda SA

Philogen SpA

Repros Therapeutics Inc

SK Chemicals Co Ltd

Takeda Pharmaceutical Co Ltd

ValiRx Plc

Viramal Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Endometriosis - Overview 8

Endometriosis - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Endometriosis - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Endometriosis - Companies Involved in Therapeutics Development 28

AbbVie Inc 28

Addex Therapeutics Ltd 28

APAvadis Biotechnologies Srl 29

Astellas Pharma Inc 29

Bayer AG 30

ElexoPharm GmbH 30

EndoCeutics Inc 31

Enteris BioPharma Inc 31

Evotec AG 32

Forendo Pharma Ltd 32

Kissei Pharmaceutical Co Ltd 33

Lipicard Technologies Ltd 33

Luye Pharma Group Ltd 33

Nippon Shinyaku Co Ltd 34

Ogeda SA 34

Philogen SpA 35

Repros Therapeutics Inc 35

SK Chemicals Co Ltd 35

Takeda Pharmaceutical Co Ltd 36

ValiRx Plc 36

Viramal Ltd 37

Endometriosis - Drug Profiles 38

acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 38

ADX-68692 - Drug Profile 39

BAY-1128688 - Drug Profile 40

BAY-1158061 - Drug Profile 41

BAY-1817080 - Drug Profile 42

BAY-1834845 - Drug Profile 43

danazol - Drug Profile 44

Drug 1 for Endometriosis - Drug Profile 45

Drug 2 for Endometriosis - Drug Profile 46

Drug 3 for Endometriosis - Drug Profile 47

Drug 4 for Endometriosis - Drug Profile 48

Drug for Endometriosis - Drug Profile 49

Drug to Antagonize P2X3 for Endometriosis - Drug Profile 50

Drug to Inhibit C-Jun for Endometriosis - Drug Profile 51

Drugs for Endometriosis and Uterine Fibroids - Drug Profile 52

EC-313 - Drug Profile 53

elagolix sodium - Drug Profile 54

fezolinetant - Drug Profile 60

FP-5677 - Drug Profile 63

goserelin ER - Drug Profile 64

KLH-2109 - Drug Profile 65

leuprolide acetate - Drug Profile 67

LT-6121 - Drug Profile 68

MIA-602 - Drug Profile 69

NHP-07 - Drug Profile 70

NS-580 - Drug Profile 71

opigolix - Drug Profile 72

Peptides for Endometriosis and Hepatic Tumor - Drug Profile 73

Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile 74

PGL-2001 - Drug Profile 75

progesterone - Drug Profile 76

Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile 77

relugolix - Drug Profile 78

SKI-2670 - Drug Profile 84

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile 85

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Oncology and Uterine Fibroids - Drug Profile 86

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 87

Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 88

Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 89

Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 90

Small Molecules to Inhibit HSD17B1 for Endometriosis - Drug Profile 91

SR-16234 - Drug Profile 92

Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy - Drug Profile 93

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 94

telapristone acetate - Drug Profile 95

tetravil - Drug Profile 104

TOT-206 - Drug Profile 106

triptorelin acetate ER - Drug Profile 107

VAL-301 - Drug Profile 108

vilaprisan - Drug Profile 109

VPE-001 - Drug Profile 111

Endometriosis - Dormant Projects 112

Endometriosis - Discontinued Products 114

Endometriosis - Product Development Milestones 115

Featured News & Press Releases 115

Appendix 127

Methodology 127

Coverage 127

Secondary Research 127

Primary Research 127

Expert Panel Validation 127

Contact Us 127

Disclaimer 128

List of Tables

List of Tables

Number of Products under Development for Endometriosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Endometriosis – Pipeline by AbbVie Inc, H2 2017

Endometriosis – Pipeline by Addex Therapeutics Ltd, H2 2017

Endometriosis – Pipeline by APAvadis Biotechnologies Srl, H2 2017

Endometriosis – Pipeline by Astellas Pharma Inc, H2 2017

Endometriosis – Pipeline by Bayer AG, H2 2017

Endometriosis – Pipeline by ElexoPharm GmbH, H2 2017

Endometriosis – Pipeline by EndoCeutics Inc, H2 2017

Endometriosis – Pipeline by Enteris BioPharma Inc, H2 2017

Endometriosis – Pipeline by Evotec AG, H2 2017

Endometriosis – Pipeline by Forendo Pharma Ltd, H2 2017

Endometriosis – Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017

Endometriosis – Pipeline by Lipicard Technologies Ltd, H2 2017

Endometriosis – Pipeline by Luye Pharma Group Ltd, H2 2017

Endometriosis – Pipeline by Nippon Shinyaku Co Ltd, H2 2017

Endometriosis – Pipeline by Ogeda SA, H2 2017

Endometriosis – Pipeline by Philogen SpA, H2 2017

Endometriosis – Pipeline by Repros Therapeutics Inc, H2 2017

Endometriosis – Pipeline by SK Chemicals Co Ltd, H2 2017

Endometriosis – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Endometriosis – Pipeline by ValiRx Plc, H2 2017

Endometriosis – Pipeline by Viramal Ltd, H2 2017

Endometriosis – Dormant Projects, H2 2017

Endometriosis – Dormant Projects, H2 2017 (Contd..1), H2 2017

Endometriosis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Endometriosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports